The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)‐fluorodeoxyglucose positron emission tomography (FDG PET), urine serum...
Saved in:
Published in | Journal of magnetic resonance imaging Vol. 27; no. 4; pp. 685 - 691 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.04.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)‐fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical/psychometric assessments are acquiredat multiple time points. All data will be cross‐linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications thatguided protocol development. A major effort was devoted toevaluating 3D T1‐weighted sequences for morphometric analyses. Several options for this sequence were optimized for the relevant manufacturer platforms and then compared in a reduced‐scale clinical trial. The protocol selected for the ADNI study includes: back‐to‐back 3D magnetization prepared rapid gradient echo (MP‐RAGE) scans; B1‐calibration scans when applicable; and an axial proton density‐T2 dual contrast (i.e., echo) fast spin echo/turbo spin echo (FSE/TSE) for pathology detection. ADNI MRI methods seek to maximize scientific utility while minimizing the burden placed on participants. The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom‐based monitoring of all scanners could be used as a model for other multisite trials. J. Magn. Reson. Imaging 2008. © 2008 Wiley‐Liss, Inc. |
---|---|
Bibliography: | Eisai Global Clinical Development Bristol-Myers Squibb Pfizer Inc. GlaxoSmithKline Institute for the Study of Aging (ISOA) Alzheimer's Disease Neuroimaging Initiative (ADNI; Principal Investigator: Michael Weiner) U.S. Food and Drug Administration ark:/67375/WNG-VMPX0FZ3-Q ArticleID:JMRI21049 National Institute on Aging Eli Lilly and Company Elan Corporation plc AstraZeneca AB Novartis Pharmaceuticals Corporation Merck & Co. Inc. Foundation for the National Institutes of Health istex:1A6BE0DAB38657571830BF221F03657300EC6088 Forest Laboratories Wyeth Research Alzheimer's Association National Institute of Biomedical Imaging and Bioengineering National Institutes of Health - No. U01 AG024904 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Address reprint requests to: C.R.J. Jr., M.D., Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail: jack.clifford@mayo.edu |
ISSN: | 1053-1807 1522-2586 |
DOI: | 10.1002/jmri.21049 |